Key Points
- CEO Robert Ainscow sold 8,438 shares on Dec. 8 at $6.20 for $52,315.60, trimming his stake to 1,546,255 shares (~$9.59M); he also sold 25,000 on Nov. 25, 67,500 on Nov. 17 and 22,500 on Oct. 14, signaling continued insider selling.
- ASP Isotopes reported a quarterly EPS of ($0.15) (missing the ($0.10) estimate) despite revenue of $4.89M, has highly negative profitability metrics (ROE −190%, net margin −1,259%), a $712M market cap, and an average analyst rating of "Hold" with a $13 price target amid mixed Buy/Sell views.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Robert Ainscow sold 8,438 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $6.20, for a total value of $52,315.60. Following the completion of the transaction, the chief executive officer directly owned 1,546,255 shares in the company, valued at approximately $9,586,781. This trade represents a 0.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Robert Ainscow also recently made the following trade(s):
- On Tuesday, November 25th, Robert Ainscow sold 25,000 shares of ASP Isotopes stock. The shares were sold at an average price of $5.77, for a total value of $144,250.00.
- On Monday, November 17th, Robert Ainscow sold 67,500 shares of ASP Isotopes stock. The stock was sold at an average price of $7.51, for a total value of $506,925.00.
- On Tuesday, October 14th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The shares were sold at an average price of $13.60, for a total value of $306,000.00.
ASP Isotopes Stock Performance
ASPI stock opened at $6.43 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The business has a 50-day moving average price of $8.43 and a 200 day moving average price of $8.71. The company has a market capitalization of $712.37 million, a P/E ratio of -5.03 and a beta of 3.41. ASP Isotopes Inc. has a 1-year low of $3.65 and a 1-year high of $14.49.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05). The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $2.25 million. ASP Isotopes had a negative return on equity of 190.44% and a negative net margin of 1,259.12%. As a group, equities research analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.
Institutional Investors Weigh In On ASP Isotopes
Several institutional investors have recently added to or reduced their stakes in ASPI. Tudor Investment Corp ET AL grew its stake in shares of ASP Isotopes by 37.5% during the third quarter. Tudor Investment Corp ET AL now owns 460,685 shares of the company's stock worth $4,432,000 after acquiring an additional 125,687 shares during the last quarter. Penn Capital Management Company LLC boosted its stake in ASP Isotopes by 983.0% in the 3rd quarter. Penn Capital Management Company LLC now owns 202,144 shares of the company's stock worth $1,945,000 after purchasing an additional 183,479 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in ASP Isotopes by 331.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 12,622 shares of the company's stock worth $121,000 after purchasing an additional 9,695 shares in the last quarter. Advisory Services Network LLC grew its position in ASP Isotopes by 125.8% during the 3rd quarter. Advisory Services Network LLC now owns 31,238 shares of the company's stock worth $301,000 after purchasing an additional 17,403 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new position in ASP Isotopes during the 3rd quarter valued at approximately $211,000. Institutional investors and hedge funds own 16.80% of the company's stock.
Analysts Set New Price Targets
ASPI has been the topic of a number of recent research reports. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Monday, November 24th. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a report on Monday. Cantor Fitzgerald started coverage on ASP Isotopes in a report on Thursday, December 4th. They issued an "overweight" rating and a $13.00 price target on the stock. Finally, Loop Capital set a $15.00 price target on ASP Isotopes in a research report on Monday, October 27th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $13.00.
View Our Latest Research Report on ASP Isotopes
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
